Neoadjuvant Immunotherapy in the Treatment of Renal Cell Carcinoma: A Case Series

Renal cell carcinoma is a type of urologic cancer that has a poor prognosis, with the majority of these being clear cell renal carcinoma. This subset has a tendency to cause disruptions in the cell cycle, making immune checkpoint inhibitors for adjuvant treatment of renal cell carcinoma the predominant pharmacological approach. Despite this, the use of immune checkpoint inhibitors in this setting is still an area of much research. In the following three different cases, we demonstrate the role and benefit of treatment with neoadjuvant immune checkpoint inhibitors in patients that have an extensive tumor burden at diagnosis, making them ineligible for operative treatment. Our hope is that these cases serve as a foreshadowing of the potential neoadjuvant treatments have in this oncological setting.